Johnson & Johnson (JNJ) stock is trading lower even after the company raised its 2026 sales forecast.
Defiance ETFs chief investment officer Sylvia Jablonski and Yahoo Finance's Julie Hyman discuss the importance of AI for Johnson & Johnson, pharmaceuticals, and biotech.
source & further reading
ca.finance.yahoo.com — original article
Meta launches Muse Wonder AI model family with frontier-level performance
OpenAI’s math breakthrough could hit biotech and pharma next
Super Micro contractor pleads guilty in scheme to divert AI servers with Nvidia chips to China